Phase IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacodynamics of AZD4831 in patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) with fibrosis.
Project objectivesThe objectives of the projects are attributable to the fields of interest of the UDR of Clinical Medicine and Hepatology: 1. Innovative treatments of advanced metabolic liver disease (MAFLD/NASH) with international multicenter intervention trials; 2. Innovative treatments of Primary Biliary Cholangitis (PBC); 3. The scouting and the characterization of MAFLD/NASH and risk factors for the evolution of chronic liver disease, including any genetic predispositions; 4. The scouting of cases of chronic Hepatitis C Virus (HCV) infection that are today susceptible to effective and well-tolerated treatment, even in elderly patients or with advanced liver disease; 5. Characterization and innovative treatments of sarcopenia in advanced chronic liver disease or malignancy; 6. Characterization of malignant and benign hepatic nodules using non-invasive techniques of temporary elastometry. |
Start and end date |
| January 2023 - Ongoing |
Project Manager |
| Vespasiani - Principal Investigator |
Coordinating institution of the project |
| UCBM |
Funding source(s). |
| Astrazeneca |